Mediar Therapeutics
PVT · PVT·Boston, MA·Private·Phase 2
Pioneering anti-fibrotic therapies that disable the myofibroblast, the key pathogenic cell driving scarring and organ failure across fibrotic diseases. Three first-in-class antibody programs target distinct fibrotic pathways (WISP1, EphrinB2, SMOC2). Lead WISP1 program licensed to Eli Lilly in a deal worth up to $687M in milestones.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Mediar Therapeutics website | Website | May 5, 2026 | 3 |